Zimmer Biomet Holdings, Inc. (ZBH)
NYSE • Healthcare
Last close at October 21, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Zimmer Biomet Holdings, Inc. keeps $9 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 13 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Zimmer Biomet Holdings beat expectations on both the top and bottom line, with second fiscal quarter of 2026 results reported on Aug. 5 showing adjusted EPS of $2.07 versus the $2.01 estimate and revenue of about $2.18 billion versus about $2.13 billion, a beat of 3% and 2%, respectively. Revenue rose 4.8% from about $2.1 billion a year ago, while gross margin held near 71% and operating margin was 15.0% as operating income reached about $326 million. Net income climbed 29.8% to about $198 million from about $153 million a year ago, and adjusted EPS was unchanged from $2.07 a year earlier. The company generated operating cash flow of about $807 million, repurchased about $500.8 million of stock, and paid about $93.4 million in dividends. Next-period consensus calls for EPS of $1.88 on revenue of $2.04 billion.
Next report — what to expect
Zimmer Biomet Holdings, Inc. (ZBH) reports earnings on November 4, 2026. Wall Street is expecting EPS of $1.88 on revenue of $2.04 billion. For trailing context, revenue grew +4.8% year over year last quarter. Zimmer Biomet has beaten EPS in 7 of 8 most recent quarters.
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. designs and sells musculoskeletal and dental implants, related surgical products, and care-enabling technology as a healthcare company focused on medical devices. Its business spans reconstructive joints, trauma, spine, dental, and procedure tools, and it generated $8.2 billion of revenue in FY2025.
Today's Snapshot
ZBH is trading 4% above yesterday's close, in line with a firmer sector. Zimmer Biomet failed to defeat a lawsuit alleging illegal commissions. ZBH reports earnings on 4 November.
Trading Volume
Below 10d avg (1.6M)
770.4K
vs S&P 500 Today
Strong Outperformance
+5.48%
Updated: October 22, 2026 at 19:19 UTC
ZBH Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$92.62 - $94.45Buy
- RSI (14)64.41Neutral
- Stochastic %K (14, 3, 3)89.63Sell
- MACD Level (12, 26)0.64Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.